Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of 15-valent HPV vaccine in healthy Chinese participants
NCT06454175Phase 1Active, not recruiting
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Start
- Aug 2024
- Primary completion
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 15-valent recombinant human papillomavirus vaccine in human papillomavirus infection (2 arms), sponsored by Shanghai Bovax Biotechnology Co., Ltd. Primary endpoints: Percentage of Participants With Adverse Events, Percentage of Participants With Solicited Adverse Events and 3 more. Started Aug 2024; status: active, not recruiting.
02
Drugs
15-valent recombinant human papillomavirus vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06454175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06454175.